Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 952

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

Open access
Pfirschke, Christina, Engblom, Camilla, Rickelt, Steffen, Cortez-Retamozo, Virna, Garris, Christopher, Pucci, Ferdinando, Yamazaki, Takahiro, Poirier-Colame, Vichnou, Newton, Andita, Redouane, Younes, Lin, Yi-Jang, Wojtkiewicz, Gregory, Iwamoto, Yoshiko, Mino-Kenudson, Mari, Huynh, Tiffany G., Hynes, Richard O., Freeman, Gordon J., Kroemer, Guido, Zitvogel, Laurence, Weissleder, Ralph, Pittet, Mikael J.·2016·Immunity
DOI 10.1016/j.immuni.2015.11.024
Open this paper in CoChat — free account

Abstract

SUMMARY Checkpoint blockade immunotherapies can be extraordinarily effective, but may benefit only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung adenocarcinoma mouse models, including genetic models, we show that autochthonous tumors that lacked T cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T cell immunity when using appropriately selected immunogenic drugs (e.g. oxaliplatin combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and lacking Trp53). The antitumor response was triggered by direct drug actions on tumor cells, relied on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended on CD8+ T cell antitumor immunity. Furthermore, instigating tumor infiltration by T cells sensitized tumors to checkpoint inhibition and controlled cancer durably. These findings indicate that the proportion of cancers responding to checkpoint therapy can be feasibly and substantially expanded by combining checkpoint blockade with immunogenic drugs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.immuni.2015.11.024

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 952

Metadata

Authors
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., Lin, Y.-J., Wojtkiewicz, G., Iwamoto, Y., Mino-Kenudson, M., Huynh, T. G., Hynes, R. O., Freeman, G. J., Kroemer, G., Zitvogel, L., Weissleder, R., & Pittet, M. J.
Venue
Immunity
Publisher
Elsevier BV
Published
2016-02
Volume
44
Issue
2
Pages
343-354
ISSN
1074-7613 (ISSN-L)
DOI
10.1016/j.immuni.2015.11.024
OpenAlex
W2252550602
Cited by
952
References
18
FWCI
44.81
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. https://app.cochat.ai/papers/10.1016/j.immuni.2015.11.024
The paper
Pfirschke, C., Engblom, C., Rickelt, S., Cortez-Retamozo, V., Garris, C., Pucci, F., Yamazaki, T., Poirier-Colame, V., Newton, A., Redouane, Y., Lin, Y.-J., Wojtkiewicz, G., Iwamoto, Y., Mino-Kenudson, M., Huynh, T. G., Hynes, R. O., Freeman, G. J., Kroemer, G., Zitvogel, L., . . . Pittet, M. J. (2016). Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity. https://doi.org/10.1016/j.immuni.2015.11.024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.